DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for cardia cancer — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCardia cancer maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cardia cancer is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ATM serine/threonine kinase (ATM) — ATM is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet anpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8OXQ · 2.5 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER (ANP). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Oncotarget · 2016 · 493 citations · open access
Metastatic spread in patients with gastric cancer
Abstract// Matias Riihimäki 1, 2 , Akseli Hemminki 3, 4 , Kristina Sundquist 2 , Jan Sundquist 2 , Kari Hemminki 1, 2 1 Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany 2 Center for Primary Health Care Research, Lund University, Malmö, Sweden 3 Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Finland 4 Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland Correspondence to: Matias Riihimäki, email: [email protected] Keywords: gastric cancer, metastasis, epidemiology Received: December 22, 2015 Accepted: June 16, 2016 Published: July 20, 2016 ABSTRACT Background: The epidemiology of metastatic gastric cancer is unexplored because cancer registries seldom cover metastatic involvement apart from “present or not”. We used a novel approach by utilizing Swedish registers to assess metastatic spread in gastric cancer. To our knowledge, this is the first nationwide description of metastases in gastric cancer. Results: The most common sites of metastasis were liver (in 48% of metastatic cancer patients), peritoneum (32%), lung (15%), and bone (12%). Metastases to the lung, nervous system, and bone were more frequent in cardia cancer and men, whereas non-cardia cancer more frequently metastasized within the peritoneum. Signet ring adenocarcinomas more frequently metastasized within the peritoneum, bone and ovaries, and less frequently to the lungs and liver compared with generic adenocarcinoma. The liver and the peritoneum were commonly single metastases while lung metastases occurred frequently together with liver metastases. The median survival in metastatic gastric cancer was 3 months, worst among those with bone and liver metastases (2 months). Methods: A total of 7,559 patients with gastric cancer were identified. Metastatic patterns and survival depending on sex, age, stage, anatomical location (cardia and non-cardia), and histological type were assessed. Conclusions: The patterns of metastasis differ notably depending on histological type. Cardia cancer exhibits a completely different metastatic behavior than non-cardia cancer. Awareness of the differing patterns may guide in tailored diagnosis of metastases. Survivors from cardia cancer would benefit from increased surveillance of extraperitoneal metastases. Bone metastases should be considered in patients with signet ring adenocarcinoma if symptoms emerge.
Application of ATP-TCA in chemotherapy of human cardia cancer
AbstractObjective To investigate the drug sensitivity of cardia tumors in vitro by ATP-TCA, and to provide basis of clinic chemotherapy. Methods 42 cardia tumors were tested by ATP-TCA to determine and assess the drug sensitivity of 8 common chemotherapeutics. Correlation analysis was done between the clinical classification and the drug sensitivity. Results The drug sensitivity had significant difference among cardia tumors. From high to low, it was ADM>MMC>PTX> 5-Fu>HCT =VP16>CDDP>IFO, Sensitive degree were 50.00 %, 35.45 %, 31.25 %, 23.53 %, 10.53 %, 10.53 %, 7.69 %, 5 %. Sensitivity of the same drug in different pathologic stages had no significant difference. Conclusion ATP-TCA can play a guiding role in individual chemotherapy for human cardia cancer.
Key words:
Stomach neoplasms; Fluorescent antibody technique; Drug therapy, combination; Microbial sensitivity test
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
